Filing Details

Accession Number:
0001104659-19-032918
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-30 21:27:10
Reporting Period:
2019-05-28
Accepted Time:
2019-05-30 21:27:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1761612 Bicycle Therapeutics Plc BCYC Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1777346 Carolyn Ng C/o Bicycle Therapeutics Plc
B900, Babraham Research Campus
Cambridge X0 CB22 3AT
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2019-05-28 1,272,733 $0.00 1,272,733 No 4 C Indirect By Vertex Global Healthcare Fund I PTE. LTD
Ordinary Shares Acquisiton 2019-05-28 141,668 $0.00 1,414,401 No 4 X Indirect By Vertex Global Healthcare Fund I PTE. LTD
Ordinary Shares Acquisiton 2019-05-28 206,767 $0.00 1,621,168 No 4 C Indirect By Vertex Global Healthcare Fund I PTE. LTD
Ordinary Shares Acquisiton 2019-05-27 571,429 $14.00 571,429 No 4 P Indirect By Vertex Venture Management PTE LTD.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Vertex Global Healthcare Fund I PTE. LTD
No 4 X Indirect By Vertex Global Healthcare Fund I PTE. LTD
No 4 C Indirect By Vertex Global Healthcare Fund I PTE. LTD
No 4 P Indirect By Vertex Venture Management PTE LTD.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Series B1 Preferred Shares Disposition 2019-05-28 1,272,733 $0.00 1,272,733 $0.00
Ordinary Shares Series B1 Preferred Shares Warrants Disposition 2019-05-28 141,668 $0.00 141,668 $0.00
Ordinary Shares Series B2 Preferred Shares Disposition 2019-05-28 206,767 $0.00 206,767 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 X Indirect
0 No 4 C Indirect
Footnotes
  1. Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
  2. Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.